Victor - The Cleaner
He lost his job at Pfizer - his whole team laid off due to 'Lack of Work'.
—
this works good if you paste
https://icandecide.org/wp-content/uploads/2023/11/125742_S59_M1_response-17aug2021.pdf
into gemini (you will have to do multi paste for size constraints. never trust the AI to read links lol.) :
LANGUAGE CHOPPING TIME - STRIP ALL THE STUFF EXCEPT THE PROCESS VIOLATIONS. UNDER EACH PROVIDE PARSIMONIOUS ANALYTIC PARAPHRASE OF THE PFIZER RESPONSE LOGIC
I got 5 right here:
Process Violations and Analytic Paraphrases
1. Deficient Documentation of Visual Inspection Failures
Violation: The firm failed to adequately document SME preliminary assessments and the rationale for allowing manufacturing to proceed following visual inspection failures (detection of residue/foreign matter). Analytic Paraphrase: Pfizer argues that while their internal Subject Matter Experts (SMEs) performed technical reviews—evaluating cleaning cycles and “dirty hold times”—the lack of a standardized recording format made these risk justifications invisible to regulators. They are substituting “ad hoc” professional judgment with a formalized SOP to bridge the gap between technical conclusion and evidentiary compliance.
2. Lack of Cleaning Validation for Building Equipment
Violation: Cleaning validation (CPQ) was not performed for specific equipment; instead, the firm relied on in-process monitoring despite a trend of contamination/residue. Analytic Paraphrase: The firm contends that the physical architecture of the system makes traditional strip-and-swab validation “impractical.” They justify the lack of formal validation by claiming that routine monitoring effectively “caught” the failure, framing a systemic validation gap as a successful detection event caused by a specific mechanical error (a misaligned spray ball) rather than a flawed cleaning strategy.
3. Inadequate Validation/Verification of Manual Cleaning
Violation: Cleaning of reusable parts via manual methods is not validated, and current verification is limited to rinse water testing rather than routine surface/swab sampling. Analytic Paraphrase: Pfizer posits that manual cleaning is inherently variable and thus “unvalidatable” by nature, shifting the burden of proof to “verification.” To address the perceived inadequacy of rinse-only testing, they are expanding their data set to include surface swabbing, essentially attempting to prove that their rigorous training and “worst-case” development studies serve as a functional surrogate for a formal validation state.
4. Inconsistent Disinfectant Efficacy Studies
Violation: Disinfectant studies failed to demonstrate consistent efficacy for required contact times across different buildings/surfaces, with some reports showing total failure on specific materials. Analytic Paraphrase: The firm attributes the observed failures to “methodological artifacts” (specifically the “under-the-plug” method) rather than ineffective chemistry. By re-testing with a “spray” method that they claim better simulates actual facility use, they are retroactively aligning their efficacy data to support existing procedures, asserting that the previous failures were a result of how the test was performed, not how the disinfectant works.
5. Failure to Monitor Controlled Areas to ISO Standards
Violation: Areas designated as ISO-rated were not monitored for particulate/microbial counts according to ISO standards, including inappropriate limits and lack of routine testing. Analytic Paraphrase: Pfizer’s defense is a “classification retreat.” They argue that ISO air quality standards for particulates are technically “not applicable” to a Drug Substance (upstream) facility. Rather than upgrading their monitoring to meet the high-level ISO designation they originally claimed, they are simply removing the ISO label and re-classifying the areas to a lower controlled status that matches their current, less-stringent monitoring capabilities.
—
>>>>>>>> Exhibit KRJ-08 pfizer
Based on a 2021 Establishment Inspection Report from Wyeth/Pfizer, Exhibit KRJ-08 is a document referencing the rejection of specific vaccine batches based on inspection results.
This document is part of a larger set of inspections related to Pfizer's BLA (Biologics License Application) for their COVID-19 vaccine.
Contextual Details from the Report:
Result: The findings led to the rejection of the referenced batches.
Date: The inspection report referencing this exhibit is dated August 21, 2021.
Context: The report includes discussions on manufacturing processes, quality control, and inspection findings related to the Pfizer-BioNTech vaccine production.
Establishment Inspection Report FEI: 1222181 Wyeth ...
The results for batches led the rejection of the batches (Exhibit KRJ-08). (b) (4). (b) (4). (b) (4).
>>>>>>>>>> what were the implications?
An August 2021 FDA inspection revealed that Pfizer rejected certain vaccine batches due to quality control deviations and insufficient data to support product quality during production scale-up. While these findings necessitated stricter investigation protocols for manufacturing deviations, studies on early commercial batches did not find a higher rate of serious adverse events. Read the full FDA Form 483 report at ICAN Decide.
Safety of BNT162b2 mRNA COVID‐19 Vaccine Batches - PMC
Summary. * Concerns about increased safety risks of early BNT162b2 vaccine batches originate from spontaneous adverse event report...
STN BL 125742/0 – COVID-19 mRNA Vaccine
Aug 18, 2021 — Review of Pfizer's Responses to the FDA Form 483 Observations. Pfizer's response to the FDA Form 483 observations was submitted on..
>>>>>>>>>> the document talks about 'cleaning' but with half the document redacted, i cannot determine if this is post-batch filtering, or inter batch equipment sanitization
In the August 2021 Establishment Inspection Report for the Pfizer Andover facility, "cleaning" refers to inter-batch equipment sanitization aimed at preventing carryover contamination. FDA observations noted deviations from validated processes, resulting in rejected batches and requirements for enhanced monitoring of cleaning procedures. Read the full inspection response at icanDecide.
Cleaning Validation in Active pharmaceutical Ingredient ...
2. Objective. The intention of this document has been to define a comprehensive approach to the Validation of Cleaning procedures ...
STN BL 125742/0 – COVID-19 mRNA Vaccine
Aug 18, 2021 — Review of Pfizer's Responses to the FDA Form 483 Observations. Pfizer's response to the FDA Form 483 observations was submitted on...
Pfizer Andover Response to the FORM FDA 483 PAI BLA ...
operation was executed in March 2021. All results obtained from this monitoring activity, including analysis, were within the spec...
The document suggests a breakdown in standard Current Good Manufacturing Practice (cGMP) protocols. By substituting active cleaning with retrospective testing, the facility bypassed a fundamental layer of contamination control.
The Core Risk: Biofilm & Residue
In pharmaceutical manufacturing, "testing for contamination" (bioburden testing) is not a substitute for "cleaning."
Storage Issues: Storing equipment uncleaned allows protein residues or media to dry and harden.
Biofilm Formation: Bacteria can form protective layers (biofilms) on stainless steel that are resistant to standard sanitization but may shed intermittently into batches.
Testing Limits: A negative contamination test doesn't prove a surface is clean; it only proves the specific swab or rinse sample didn't pick up enough microbes to grow in a lab culture.
Practical Implications
Post-Hoc Validation: They were essentially "testing quality into the product" rather than "building quality into the process." If a test came back positive, the entire batch was already at risk.
Accumulative Contamination: Without inter-batch cleaning, small amounts of residue from "Batch A" can degrade or react, potentially contaminating "Batch B" through cross-contamination or chemical carryover.
Regulatory Failure: This is a classic "Observation 483" or Warning Letter trigger. Regulators view "testing instead of cleaning" as a failure of the Quality Management System (QMS) because it relies on luck rather than a controlled environment.
Impact on Rejections
The rejections mentioned in the exhibit likely occurred because the "post-batch testing" eventually caught a contamination event that the lack of cleaning made inevitable. This creates a "spike" in failures rather than a steady, predictable manufacturing flow.
Do you want to look for specific FDA Warning Letters or Form 483s issued to that site to see how the agency officially categorized those cleaning failures?
FDA warning letters
In the pharmaceutical industry, an FDA Warning Letter is a formal escalation that follows an inspection where serious violations of current Good Manufacturing Practice (cGMP) were found.
While the specific document you are referencing (KRJ-08) is an Establishment Inspection Report (EIR) rather than a Warning Letter, it details the "objectionable conditions" that could lead to one.
Key Distinctions in FDA Enforcement
Form 483 (Inspectional Observations): Issued at the end of an inspection. It lists specific concerns (like the cleaning issues you noted) for the company to address voluntarily.
Warning Letter: Issued months later if the company’s response to the 483 is inadequate. It is a public notification that the FDA may take legal action or withhold product approvals.
Relevant Pfizer Inspection History
Historically, Pfizer has received Warning Letters for similar "loss of control" issues at other facilities, which provides context for why the cleaning practices in KRJ-08 were scrutinized:
McPherson, Kansas (2017): A major Warning Letter was issued for "out of control" manufacturing, including particulate contamination (cardboard and glass in vials) and inadequate aseptic techniques.
Andover, Massachusetts (2021): The EIR referencing KRJ-08 was part of the BLA (Biologics License Application) process for the COVID-19 vaccine. It noted recurrent deviations, including one where multiple final batches showed lower-than-expected results.
Vizag, India (2020): A Warning Letter cited significant cGMP violations regarding finished pharmaceuticals.
Regulators typically cite this as a failure to validate cleaning procedures. According to FDA Guidance on Cleaning Validation, a company cannot rely on testing the final product to prove the equipment was clean.
The primary dangers cited in these letters often include:
Cross-Contamination: Residue from previous batches (or cleaning agents) remaining on equipment.
Microbial Growth: Hold times that exceed validated limits allow bacteria to proliferate.
Inadequate Investigation: Failure to find the "root cause" when contamination is eventually detected.
of 3
Hi all, a while ago I did a AI dive and learned (hopefully not a hallucination) that if there was a 20th second delay in the high pressure streams that there could be species created that would later degrade the good particles in the batch. a few bad seeds could wreck fill the vial. confirm? The AI mentioned that because of this, the batch is started, run for a few minutes, and the first bit of production is supposed to be thrown away - lest the ill-formed products ruin the batch by domino effect.
The AI also mentioned that CLEANING THE EQUIPMENT in between runs was essential to making a safe nanoparticle batch. What if a ‘pathological particle’ gets made in one batch, and then sits in the machine until the next batch?
“(Exhibit KRJ-08) pfizer” - read up on cleaning.
Based on a 2021 Establishment Inspection Report from Wyeth/Pfizer, Exhibit KRJ-08 is a document referencing the rejection of specific vaccine batches based on inspection results. [https://phmpt.org/wp-content/uploads/2023/11/116_BLA-125742-0_08-21-2021_Inspection-Related_Establi.pdf]
>>>>>>>> what if plasmid DNA and small SV40 framents were in the stream?
If plasmid DNA (pDNA) or SV40 DNA fragments were present in the aqueous stream alongside the mRNA, they would be encapsulated into the Lipid Nanoparticles (LNPs) through the exact same mechanism as the mRNA.
The LNP doesn’t have a “filter” to distinguish between the intended mRNA and accidental DNA—it simply reacts to electrical charges.
1. The Co-Encapsulation Process
During the impingement jet mixing, the ionizable lipids are positively charged. They are looking for negatively charged molecules to bind with. Both mRNA and DNA are highly negative due to their phosphate backbones.
Competition: The DNA fragments would compete with the mRNA for space inside the lipid shell.
Indiscriminate Wrapping: The “crash” of the two streams is so fast that the lipids will wrap around any genetic material present in the aqueous phase.
The Result: You would end up with “hybrid” LNPs containing both the intended vaccine payload and the DNA contaminants.
2. Biological Implications
If DNA fragments (like the SV40 promoter/enhancer or pDNA) are packaged into LNPs, the LNP does its job: it protects that DNA from being destroyed by enzymes in your blood and delivers it directly into your cells.
Cellular Entry: Once inside the cell, the LNP releases its cargo into the cytoplasm.
Nuclear Access: While mRNA stays in the cytoplasm to be translated into protein, DNA typically needs to enter the nucleus to be functional. Small fragments or plasmids have a much harder time entering the nucleus than mRNA has staying in the cytoplasm, but the LNP delivery system makes the initial hurdle (the cell membrane) trivial.
Integration Risk: The primary concern regarding DNA contamination is insertional mutagenesis—the theoretical risk that the DNA could integrate into the host’s genome. Regulatory bodies like the FDA and EMA have established strict limits on “Residual DNA” (typically 10 ng per dose and a certain size limit) to ensure these risks remain negligible.
3. Why would they be there?
In the Pfizer/BioNTech process (specifically “Process 2”), the mRNA is created using a DNA template (the plasmid).
Standard Step: After the mRNA is “printed” from the DNA, an enzyme called DNase is added to “chew up” and remove the DNA template.
The Issue: If the DNase step is incomplete, or if the purification filters don’t catch the fragments, those DNA pieces remain in the aqueous stream. When that stream hits the lipid stream, the DNA gets “shrink-wrapped” into the vaccine particles.
>>>>>>>> so the particle produced would not match the specification
Exactly. From a pharmaceutical manufacturing and regulatory standpoint, if significant amounts of DNA (whether full plasmids or SV40 fragments) are encapsulated, the final product is out of specification (OOS).
Here is why that mismatch is a critical issue for the manufacturer:
1. The “Cargo” Ratio is Altered
The potency of the vaccine is based on the concentration of mRNA. If the LNP is occupied by DNA fragments, you are essentially “filling the suitcase” with the wrong luggage.
Reduced Potency: If 5% of your LNPs contain DNA instead of mRNA, the effective dose of the vaccine is lower than what is stated on the label.
Inconsistent Dosing: Because the mixing is stochastic (random), you may end up with a heterogeneous population of particles—some with mRNA, some with DNA, and some with both.
2. Physical Stability and Size
LNPs are engineered to a very specific size (usually around 60–100 nanometers) and a specific polydispersity index (PDI), which measures how uniform the particles are.
Size Changes: Plasmid DNA is much larger and more rigid than the single-stranded mRNA it was meant to produce. Large DNA molecules can change the physics of the LNP formation, potentially leading to larger or misshapen particles that don’t behave correctly in the body.
Aggregation: Out-of-spec particles are more likely to clump together (aggregate), which can affect how the vaccine is absorbed by the lymphatic system.
3. Regulatory and Safety Specifications
The “Specification” isn’t just a suggestion; it’s a legal requirement for the batch to be released. Pfizer and BioNTech must adhere to limits set by agencies like the FDA and EMA:
Residual DNA Limits: The current standard limit is 10 ng of DNA per dose.
DNA Integrity: Regulatory agencies also look at the size of the DNA. Smaller fragments (under 200 base pairs) are generally considered lower risk than large, functional sequences like the SV40 promoter or a full antibiotic-resistance gene from the plasmid.
4. The “Process 1” vs. “Process 2” Gap
This specific issue became a point of discussion because the early clinical trials used Process 1 (PCR-based, very clean), whereas the mass-production for the public used Process 2 (Plasmid-based in E. coli vats).
In Process 2, the DNA template must be aggressively removed.
If the purification steps (like chromatography and DNase digestion) don’t perform to the validated specification, the “streams” carry that DNA into the mixer, and the resulting LNP is no longer the “pure” product described in the initial regulatory filings.
Summary of the “Spec” Failure
If DNA is present in the stream, the resulting particle is technically a DNA/RNA Hybrid LNP. Since the product is marketed and authorized specifically as a Modified mRNA Vaccine, the presence of unintended genetic material represents a failure in the purification “specification,” regardless of whether the amount is deemed “safe” or not by regulators.
